Primary Sclerosing Cholangitis Market is Estimated to Witness High Growth Owing to Opportunity in Early Disease Diagnosis

Primary Sclerosing Cholangitis Market


Primary Sclerosing Cholangitis (PSC) is a chronic and progressive cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts that can ultimately lead to cirrhosis and death from complications of end-stage liver disease. PSC can occur alone or may be associated with inflammatory bowel disease, mainly ulcerative colitis. The main product types associated with PSC are magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangioscopy and liver biopsy. These products play an important role in accurate diagnosis of PSC in early stages.

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

Early diagnosis of PSC can help doctors to closely monitor the disease progression and recommend timely treatment interventions. This presents a major market opportunity for diagnostic devices manufacturers to develop advanced solutions that aid accurate diagnosis of PSC in early stages. Technologies exploiting biomarkers and molecular signatures hold promise for early non-invasive diagnosis before symptoms appear or disease progresses. This will help address the unmet need of early disease detection and improve patient outcomes.

Porter's Analysis
Threat of new entrants: The primary sclerosing cholangitis market requires high investments in R&D to develop new drugs and therapies. The presence of major players also increases the switch cost for patients, lowering the threat of new entrants.
Bargaining power of buyers: The bargaining power of buyers is moderate as primary sclerosing cholangitis has no cure and patients rely on doctors for advice on treatment. However, availability of generic drugs provides options.
Bargaining power of suppliers: The major suppliers in this market include pharmaceutical companies and medical device manufacturers. Their bargaining power is high due to patented drugs and differentiated products.
Threat of new substitutes: There is no substitute for drugs used to treat primary sclerosing cholangitis. Alternatives include liver transplant which is the last option.
Competitive rivalry: The competitive rivalry is high among major players due to their focus on R&D and new drug launches.

SWOT Analysis
Strength: Availability of large patient pool, increasing healthcare expenditure, and growing awareness about the disease provide market opportunities.
Weakness: Lack of approved drugs for treatment and difficulties in early diagnosis limit growth.
Opportunity: Uptake of newly approved drugs and expansion in emerging markets will drive the market. Government initiatives to reduce disease burden offer scope.
Threats: High treatment costs, risk of complications post-transplant, and reimbursement issues in some countries pose challenges.

Key Takeaways
Global Primary Sclerosing Cholangitis Market Demand is expected to witness high growth over the forecast period supported by rising disease prevalence. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030.

North America currently dominates the market due to developed healthcare infrastructure and patient awareness. Regional analysis shows Europe is the second largest market and is expected to grow at a significant rate throughout the forecast period. The launch of novel drugs provides lucrative opportunities.

Key players in the primary sclerosing cholangitis market are Abbott Point of Care Inc., Cornley Hi-tech Co., LTD, Radiometer Medical ApS, EDAN Instruments, Inc., ERBA Diagnostics Mannheim GmbH, F Hoffman La Roche Ltd., Fortress Diagnostics, Instrumentation Laboratories, LifeHealth, Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems, Inc., Sensa Core, and Siemens Medical Solutions USA, Inc. Major pharmaceutical companies are focusing on developing new advanced drug therapies and combination therapies to treat primary sclerosing cholangitis more effectively. 

Comments

Post a Comment

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

Image
Security Robot Market The Security Robot Market is estimated to be valued at US$ 11.8 billion in 2022 and is expected to exhibit a CAGR of 12.87% over the forecast period of 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Security Robot Market encompasses advanced robotic technologies that are specifically designed and developed to enhance security and surveillance operations. These robots are equipped with features such as video surveillance, thermal imaging, facial recognition, and intrusion detection, among others. They are extensively used by security agencies and organizations across various sectors, including residential, commercial, industrial, and government, to enhance safety, reduce human intervention, and streamline security operations. Security robots offer real-time monitoring, remote control, and high accuracy, making them an ideal choice for surveillance in sensitive areas and remote locations. Market Dynamics:
Read more

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027

Image
  Scottish Whisky Market The Scottish Whisky Market is a captivating landscape that has been evolving and transforming over the years. It is a world of tradition, craftsmanship, and heritage, where every drop of whisky tells a story. The history of Scottish whisky traces back centuries, with the earliest records dating back to the 15th century. Whisky production initially started in monasteries, where monks distilled spirits for medicinal purposes. Over time, whisky production moved from monastic settings to farms and then to commercial distilleries. This transition marked the beginning of an industry that would become synonymous with Scotland. Scottish Whisky Market Was Valued At US$ 4.97 Bn In 2018, And It Is Expected To Reach US$ 7.89 Bn By The End Of 2027, Exhibiting A CAGR Of 5.3% During The Forecast Period (2019 To 2027). One of the defining characteristics of the Scottish Whisky Market is its adherence to traditional production methods. Scotch whisky is made from malted b
Read more

Monochloroacetic Acid (MCAA) Market Is Estimated To Witness High Growth Owing To Increasing Demand for Surfactants and Herbicides

Image
Monochloroacetic Acid (MCAA) Market The Monochloroacetic Acid (MCAA) Market is estimated to be valued at USD 676.52 Million in 2022 and is expected to exhibit a CAGR of 7.03% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Monochloroacetic Acid (MCAA) Market is driven by the increasing demand for surfactants and herbicides in several industries such as agriculture, pharmaceuticals, textiles, and personal care. MCAA is extensively used in the production of surfactants, herbicides, and carboxymethyl cellulose (CMC), which are essential in various applications. These applications include detergents, agrochemicals, pharmaceuticals, dyes, and cosmetics, among others. The versatile properties of MCAA, such as its ability to act as a raw material in the production of herbicides and surfactants, make it highly desirable in the market. Market Dynamics: The Monochloroacetic Acid (MCAA) Market is driven by two k
Read more